Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Lei Lei Wu

News Reporter

Aura Biosciences said eight of 10 patients with a rare eye cancer who received a therapeutic dose of its experimental virus-like drug conjugate saw their …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients

Lei Lei Wu

News Reporter

Sign up to read this article for free.

Director of IT, Security

Viridian Therapeutics

Waltham, MA, USA

Bad trip: How culture conflict and a need for cash nearly broke Lykos

After landing a key win in a common cancer condition, Pfizer faces a big test in Phase 3

23andMe heads to ESMO to tout its two clinical-stage drugs after scrapping discovery team

Cigna sues FTC, calling for withdrawal of 'biased, erroneous' PBM report

Merck and Daiichi’s rejected HER3 ADC clears a Phase 3 in certain lung cancers

Breaking down silos with a new quantitative approach to drug development

Au­ra's in­frared light-ac­ti­vat­ed drug stops tu­mor growth and pre­serves vi­sion in eight eye can­cer pa­tients

News Reporter

Sign up to read this article for free.

Viridian Therapeutics

Waltham, MA, USA

Aura's infrared light-activated drug stops tumor growth and preserves vision in eight eye cancer patients